Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE U.S. HEMATOLOGY ONCOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 U.S. HEMATOLOGY ONCOLOGY MARKET: GEOGRAPHICAL SCOPE
2.3 U.S. HEMATOLOGY ONCOLOGY MARKET: YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 U.S. HEMATOLOGY ONCOLOGY MARKET: MULTIVARIATE MODELLING
2.7 DBMR MARKET POSITION GRID
2.8 VENDOR SHARE ANALYSIS
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 INDUSTRY INSIGHTS
4.4 RWE/RWD PRACTICE, EREGISTERS, EHEALTH PROGRAMS FOR ONCO/AID/RARE DISEASES
4.4.1 PROMOTIONAL ACTIVITIES OF COMPANIES
4.5 TENDER SYSTEM AND CLINICAL GUIDELINES
4.5.1 ORGANIZATION OF THE TENDER SYSTEM
4.5.2 CLINICAL GUIDELINES (NATIONAL/REGIONAL/LOCAL HOSPITAL)
4.5.2.1 NATIONAL GUIDELINES (STANDARDIZED ACROSS THE U.S.)
4.5.2.2 REGIONAL GUIDELINES (STATE-LEVEL & RESEARCH INSTITUTION-BASED)
4.5.2.3 LOCAL HOSPITAL GUIDELINES (INSTITUTION-SPECIFIC PROTOCOLS)
4.6 MARKET CHARACTERISTICS (DECENTRALIZED/ HIGHLY FRAGMENTED)
5 NUMBER OF ONGOING CLINICAL TRIALS FOR EACH TREATMENT TYPE
5.1 TARGETED THERAPIES & SMALL MOLECULES
5.1.1 TYROSINE KINASE INHIBITORS (TKIS)
5.1.2 MONOCLONAL ANTIBODIES
5.2 IMMUNOTHERAPIES
5.2.1 CART CELL THERAPY
5.2.2 IMMUNE CHECKPOINT INHIBITORS
5.2.3 CYTOKINE THERAPY
5.3 CHEMOTHERAPY DRUGS
5.3.1 ALKYLATING AGENTS
5.3.2 ANTHRACYCLINES
5.3.3 TOPOISOMERASE INHIBITORS
5.3.4 VINCA ALKALOIDS
5.4 STEM CELL TRANSPLANTATION
5.4.1 AUTOLOGOUS STEM CELL TRANSPLANTATION
5.4.2 ALLOGENEIC STEM CELL TRANSPLANTATION
5.5 GENE THERAPY
5.6 EXTRA DRUGS AS PER REQUIREMENT
5.6.1 VENETECLAX HMA
5.6.2 CAR NK CELLS
5.6.3 MENIN INHIBITORS
6 CUSTOMIZATION
6.1 THERAPY CLASSIFICATION
6.1.1 THERAPY PURPOSE
6.1.1.1 THERAPIES DELAYING TRANSPLANT
6.1.1.2 THERAPIES EXPANDING INDICATION FOR TRANSPLANT
6.1.2 COST ANALYSIS
6.2 MARKET INDUSTRY TRENDS AND FORECAST
6.3 SHIFT IN CARE SETTINGS
6.4 TREATMENT TYPES AS PER REQUIREMENT
6.4.1 VENETOCLAX (HMA) COMBINATION
6.4.2 CAR NK CELLS
6.5 HEALTHCARE PROVIDERS AND FACILITIES
6.5.1 PROVIDER MARKET:
6.5.1.1 TOTAL ADDRESSABLE PROVIDER MARKET FOR HEMATOLOGIC MALIGNANCIES (AML, ALL, MDS, APLASTIC ANEMIA, SICKLE CELL DISEASE)
6.5.1.2 NUMBER OF HEMATOLOGISTS/ONCOLOGISTS TREATING THESE CONDITIONS
6.5.1.3 GEOGRAPHIC DISTRIBUTION OF THESE PROVIDERS
6.5.1.4 PROVIDERS PRACTICING AT NON-TRANSPLANT CENTERS NEEDING TO REFER PATIENTS EXTERNALLY FOR TRANSPLANTS
6.5.2 HEALTHCARE FACILITIES TRENDS:
6.5.2.1 NUMBER OF HEALTHCARE FACILITIES EQUIPPED TO DELIVER EACH TREATMENT
6.5.2.2 GEOGRAPHIC TRENDS IN THE NUMBER OF HEALTHCARE FACILITIES OVER DEFINED YEARS
6.5.3 TRANSPLANT CENTERS
7 U.S. HEMATOLOGY ONCOLOGY MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES TRANSFORMING HEMATOLOGY ONCOLOGY DETECTION AND TREATMENT APPROACHES
8.1.2 DEVELOPMENT OF TARGETED THERAPIES AND IMMUNOTHERAPIES IN HEMATOLOGY ONCOLOGY CARE
8.1.3 CONSOLIDATION OF HEMATOLOGY ONCOLOGY PRACTICES IMPROVING TREATMENT EFFICIENCY AND PATIENT OUTCOMES
8.2 RESTRAINTS
8.2.1 PATIENT NON-COMPLIANCE WITH TREATMENT REGIMENS IN HEMATOLOGY ONCOLOGY CARE
8.2.2 LACK OF EARLY DETECTION IN HEMATOLOGY ONCOLOGY IMPEDING PROGRESS
8.3 OPPORTUNITIES
8.3.1 RISING INCIDENCE OF CANCER LEADS TO INCREASED DEMAND FOR TREATMENTS
8.3.2 INCREASE IN THE NUMBER OF COLLABORATIVE PARTNERSHIPS THAT ACCELERATE ADVANCEMENTS IN CANCER TREATMENTS
8.4 CHALLENGES
8.4.1 RISING COSTS ASSOCIATED WITH THE CANCER TREATMENTS
8.4.2 SHORTAGE OF THE HEALTHCARE PROFESSIONALS TRAINED IN HEMATOLOGY ONCOLOGY
9 U.S. HEMATOLOGY ONCOLOGY MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 LYMPHOMA
9.3 ACUTE MYELOID LEUKEMIA (AML)
9.4 MYELODYSPLASTIC SYNDROMES (MDS)
9.5 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
9.6 SICKLE CELL DISEASE (SCD)
9.7 OTHERS
10 U.S. HEMATOLOGY ONCOLOGY MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALIZED CLINICS
10.4 TRANSPLANT CENTERS
10.5 PHARMACEUTICAL & BIOTECH COMPANIES
10.6 OTHERS
11 U.S. HEMATOLOGY ONCOLOGY MARKET, BY RACE
11.1 OVERVIEW
11.2 WHITE OR UNKNOWN RACE
11.3 ETHNICALLY DIVERSE
11.3.1 BLACK OR AFRICAN AMERICAN
11.3.2 HISPANIC
11.3.3 ASIAN OR PACIFIC ISLANDER (INCLUDING HAWAIIAN)
11.3.4 AMERICAN INDIAN OR ALASKA NATIVE
11.3.5 MULTIPLE RACE
12 U.S. HEMATOLOGY ONCOLOGY MARKET, BY TREATMENT TYPE
12.1 OVERVIEW
12.2 TARGETED THERAPIES & SMALL MOLECULES
12.2.1 TYROSINE KINASE INHIBITORS (TKIS)
12.2.1.1 IMATINIB
12.2.1.2 DASATINIB
12.2.1.3 NILOTINIB
12.2.1.4 IBRUTINIB
12.2.1.5 ACALABRUTINIB
12.2.2 MONOCLONAL ANTIBODIES
12.2.2.1 RITUXIMAB
12.2.2.2 OBINUTUZUMAB
12.2.2.3 OFATUMUMAB
12.2.2.4 DARATUMUMAB
12.2.2.5 ELOTUZUMAB
12.2.3 PROTEASOME INHIBITORS
12.2.3.1 BORTEZOMIB
12.2.3.2 CARFILZOMIB
12.2.3.3 IXAZOMIB
12.2.4 FLT3 INHIBITORS
12.2.4.1 MIDOSTAURIN
12.2.4.2 GILTERITINIB
12.3 IMMUNOTHERAPIES
12.3.1 CART CELL THERAPY
12.3.1.1 TISAGENLECLEUCEL
12.3.1.2 AXICABTAGENE CILOLEUCEL
12.3.1.3 BREXUCABTAGENE AUTOLEUCEL
12.3.1.4 LISOCABTAGENE MARALEUCEL
12.3.2 IMMUNE CHECKPOINT INHIBITORS
12.3.2.1 PEMBROLIZUMAB
12.3.2.2 NIVOLUMAB
12.3.3 BISPECIFIC ANTIBODIES
12.3.4 CYTOKINE THERAPY
12.3.4.1 INTERFERONS
12.3.4.2 INTERLEUKINS
12.3.4.3 OTHERS
12.4 CHEMOTHERAPY DRUGS
12.4.1 ALKYLATING AGENTS
12.4.1.1 CYCLOPHOSPHAMIDE
12.4.1.2 CHLORAMBUCIL
12.4.1.3 BENDAMUSTINE
12.4.2 ANTIMETABOLITES
12.4.2.1 CYTARABINE (ARA C)
12.4.2.2 METHOTREXATE
12.4.2.3 FLUDARABINE
12.4.2.4 MERCAPTOPURINE
12.4.3 ANTHRACYCLINES
12.4.3.1 DOXORUBICIN
12.4.3.2 DAUNORUBICIN
12.4.3.3 IDARUBICIN
12.4.4 TOPOISOMERASE INHIBITORS
12.4.4.1 ETOPOSIDE
12.4.4.2 TOPOTECAN
12.4.5 VINCA ALKALOIDS
12.4.5.1 VINCRISTINE
12.4.5.2 VINBLASTINE
12.5 STEM CELL TRANSPLANTATION
12.5.1 AUTOLOGOUS STEM CELL TRANSPLANTATION
12.5.2 ALLOGENEIC STEM CELL TRANSPLANTATION
12.5.2.1 MATCHED RELATED DONOR (MRD)
12.5.2.2 MATCHED UNRELATED DONOR (MUD)
12.5.2.3 HAPLOIDENTICAL DONOR
12.5.2.4 OTHERS
12.6 GENE THERAPY
12.6.1 CRISPR-CAS9 BASED THERAPIES
12.6.2 LENTIGLOBIN BB305
12.6.3 OTHERS
13 U.S. HEMATOLOGY ONCOLOGY MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: U.S.
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 GILEAD SCIENCE, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 ABBVIE INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PIPELINE PRODUCT PORTFOLIO
15.3.4 RECENT/NEWS
15.4 ASTRAZENECA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 SANOFI
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ASTELLAS PHARMA INC.
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BAYER AG
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 BLUEBIRD BIO, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BRISTOL-MYERS SQUIBB COMPANY
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT NEWS
15.1 CITY OF HOPE.
15.10.1 COMPANY SNAPSHOT
15.10.2 SERVICE PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 CLEVELAND CLINIC TAUSSIG CANCER
15.11.1 COMPANY SNAPSHOT
15.11.2 SERVICES PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 CRISPR THERAPEUTICS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 DANA-FARBER CANCER INSTITUTE, INC.
15.13.1 COMPANY SNAPSHOT
15.13.2 SERVICE PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 DKMS GROUP GGMBH
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 EDITAS MEDICINE
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT NEWS
15.16 ELI LILLY AND COMPANY
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 F. HOFFMANN-LA ROCHE LTD.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 FRED HUTCHINSON CANCER CENTER
15.18.1 COMPANY SNAPSHOT
15.18.2 SERVICE PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT/NEWS
15.2 MEMORIAL SLOAN KETTERING CANCER CENTER
15.20.1 COMPANY SNAPSHOT
15.20.2 SERVICE PORTFOLIO
15.20.3 RECENT UPDATES
15.21 MERCK & CO., INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 MOFFITT CANCER CENTER
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT/NEWS
15.23 NOVARTIS AG
15.23.1 COMPANY SNAPSHOT
15.23.2 REVENUE ANALYSIS
15.23.3 PRODUCT PORTFOLIO
15.23.4 RECENT DEVELOPMENT
15.24 PFIZER INC.
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
15.25 REGENERON PHARMACEUTICALS INC.
15.25.1 COMPANY SNAPSHOT
15.25.2 REVENUE ANALYSIS
15.25.3 PRODUCT PORTFOLIO
15.25.4 RECENT DEVELOPMENT
15.26 ROSEWELL PARK COMPREHENSIVE CANCER CENTER
15.26.1 COMPANY SNAPSHOT
15.26.2 SERVICE PORTFOLIO
15.26.3 RECENT DEVELOPMENT
15.27 STANFORD MEDICINE
15.27.1 COMPANY SNAPSHOT
15.27.2 SERVICE PORTFOLIO
15.27.3 RECENT UPDATES
15.28 THE JOHNS HOPKINS UNIVERSITY, THE JOHNS HOPKINS HOSPITAL, AND JOHNS HOPKINS HEALTH SYSTEM
15.28.1 COMPANY SNAPSHOT
15.28.2 PRODUCT PORTFOLIO
15.28.3 RECENT DEVELOPMENTS
15.29 THE UNIVERSITY OF CHICAGO MEDICAL CENTER
15.29.1 COMPANY SNAPSHOT
15.29.2 SERVICE PORTFOLIO
15.29.3 RECENT DEVELOPMENT
15.3 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
15.30.1 COMPANY SNAPSHOT
15.30.2 SERVICE PORTFOLIO
15.30.3 RECENT UPDATES/NEWS
15.31 THE CHILDREN'S HOSPITAL OF PHILADELPHIA
15.31.1 COMPANY SNAPSHOT
15.31.2 SERVICE PORTFOLIO
15.31.3 RECENT DEVELOPMENT
15.32 UCLA HEALTH
15.32.1 COMPANY SNAPSHOT
15.32.2 PRODUCT PORTFOLIO
15.32.3 RECENT DEVELOPMENT/NEWS
15.33 UNIVERSITY OF UTAH HEALTH
15.33.1 COMPANY SNAPSHOT
15.33.2 SERVICE PORTFOLIO
15.33.3 RECENT DEVELOPMENT
15.34 USC NORRIS COMPREHENSIVE CANCER
15.34.1 COMPANY SNAPSHOT
15.34.2 PRODUCT PORTFOLIO
15.34.3 RECENT DEVELOPMENT/NEWS
15.35 VANDERBILT-INGRAM CANCER CENTER
15.35.1 COMPANY SNAPSHOT
15.35.2 PRODUCT PORTFOLIO
15.35.3 RECENT DEVELOPMENT
15.36 VERTEX PHARMACEUTICALS INCORPORATED
15.36.1 COMPANY SNAPSHOT
15.36.2 REVENUE ANALYSIS
15.36.3 PRODUCT PORTFOLIO
15.36.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 U.S. HEMATOLOGY ONCOLOGY MARKET, BY DISEASE TYPE, 2018-2035 (USD MILLION)
TABLE 2 U.S. HEMATOLOGY ONCOLOGY MARKET, BY END USER, 2018-2035 (USD MILLION)
TABLE 3 U.S. HEMATOLOGY ONCOLOGY MARKET, BY RACE, 2018-2035 (USD MILLION)
TABLE 4 U.S. ETHNICALLY DIVERSE IN HEMATOLOGY ONCOLOGY MARKET, BY CATEGORY, 2018-2035 (USD MILLION)
TABLE 5 U.S. HEMATOLOGY ONCOLOGY MARKET, BY TREATMENT TYPE, 2018-2035 (USD MILLION)
TABLE 6 U.S. TARGETED THERAPIES & SMALL MOLECULES IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 7 U.S. TYROSINE KINASE INHIBITORS (TKIS) IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 8 U.S. MONOCLONAL ANTIBODIES IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 9 U.S. PROTEASOME INHIBITORS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 10 U.S. FLT3 INHIBITORS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 11 U.S. IMMUNOTHERAPIES IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 12 U.S. CART CELL THERAPY IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 13 U.S. IMMUNE CHECKPOINT INHIBITORS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 14 U.S. BISPECIFIC ANTIBODIES IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 15 U.S. CYTOKINE THERAPY IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 16 U.S. CHEMOTHERAPY DRUGS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 17 U.S. ALKYLATING AGENTS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 18 U.S. ANTIMETABOLITES IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 19 U.S. ANTHRACYCLINES IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 20 U.S. TOPOISOMERASE INHIBITORS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 21 U.S. VINCA ALKALOIDS IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 22 U.S. STEM CELL TRANSPLANTATION IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 23 U.S. ALLOGENEIC STEM CELL TRANSPLANTATION IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
TABLE 24 U.S. GENE THERAPY IN HEMATOLOGY ONCOLOGY MARKET, BY TYPE, 2018-2035 (USD MILLION)
List of Figure
FIGURE 1 U.S. HEMATOLOGY ONCOLOGY MARKET: SEGMENTATION
FIGURE 2 U.S. HEMATOLOGY ONCOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 U.S. HEMATOLOGY ONCOLOGY MARKET: DROC ANALYSIS
FIGURE 4 U.S. HEMATOLOGY ONCOLOGY MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 5 U.S. HEMATOLOGY ONCOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. HEMATOLOGY ONCOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. HEMATOLOGY ONCOLOGY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 U.S. HEMATOLOGY ONCOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 U.S. HEMATOLOGY ONCOLOGY MARKET: SEGMENTATION
FIGURE 10 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES TRANSFORMING HEMATOLOGY ONCOLOGY DETECTION AND TREATMENT APPROACHES ARE DRIVING THE GROWTH OF THE U.S. HEMATOLOGY ONCOLOGY MARKET FROM 2025 TO 2035
FIGURE 11 THE LYMPHOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. HEMATOLOGY ONCOLOGY MARKET IN 2025 AND 2035
FIGURE 12 U.S. HEMATOLOGY ONCOLOGY MARKET EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 SIX SEGMENTS COMPRISE THE U.S. HEMATOLOGY ONCOLOGY MARKET, BY DISEASE TYPE (2024)
FIGURE 15 DROC ANALYSIS
FIGURE 16 U.S. HEMATOLOGY ONCOLOGY MARKET: BY DISEASE TYPE, 2024
FIGURE 17 U.S. HEMATOLOGY ONCOLOGY MARKET: BY DISEASE TYPE, 2025 TO 2035 (USD MILLION)
FIGURE 18 U.S. HEMATOLOGY ONCOLOGY MARKET: BY DISEASE TYPE, CAGR (2025-2035)
FIGURE 19 U.S. HEMATOLOGY ONCOLOGY MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 U.S. HEMATOLOGY ONCOLOGY MARKET: BY END USER, 2024
FIGURE 21 U.S. HEMATOLOGY ONCOLOGY MARKET: BY END USER, 2025 TO 2035 (USD MILLION)
FIGURE 22 U.S. HEMATOLOGY ONCOLOGY MARKET: BY END USER, CAGR (2025- 2035)
FIGURE 23 U.S. HEMATOLOGY ONCOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 24 U.S. HEMATOLOGY ONCOLOGY MARKET: BY RACE, 2024
FIGURE 25 U.S. HEMATOLOGY ONCOLOGY MARKET: BY RACE, 2025 - 2035 (USD MILLION)
FIGURE 26 U.S. HEMATOLOGY ONCOLOGY MARKET: BY RACE, CAGR (2025- 2035)
FIGURE 27 U.S. HEMATOLOGY ONCOLOGY MARKET: BY RACE, LIFELINE CURVE
FIGURE 28 U.S. HEMATOLOGY ONCOLOGY MARKET: BY TREATMENT TYPE, 2024
FIGURE 29 U.S. HEMATOLOGY ONCOLOGY MARKET: BY TREATMENT TYPE, 2025-2035 (USD MILLION)
FIGURE 30 U.S. HEMATOLOGY ONCOLOGY MARKET: BY TREATMENT TYPE, CAGR (2025-2035)
FIGURE 31 U.S. HEMATOLOGY ONCOLOGY MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 32 U.S. HEMATOLOGY ONCOLOGY MARKET: COMPANY SHARE 2024 (%)
